Enlivex Therapeutics Ltd.
ENLV
$1.05
-$0.05-4.55%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -15.01M | -18.93M | -22.29M | -25.99M | -29.07M |
| Total Depreciation and Amortization | 545.00K | 709.00K | 762.00K | 814.00K | 835.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.68M | 4.89M | 4.30M | 4.70M | 6.53M |
| Change in Net Operating Assets | -1.22M | -870.00K | 212.00K | -1.77M | -1.82M |
| Cash from Operations | -13.01M | -14.20M | -17.02M | -22.25M | -23.52M |
| Capital Expenditure | -103.00K | -75.00K | -95.00K | -117.00K | -236.00K |
| Sale of Property, Plant, and Equipment | 2.29M | 2.05M | 276.00K | 357.00K | 133.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6.87M | 7.86M | 12.20M | 10.24M | -25.87M |
| Cash from Investing | 9.06M | 9.84M | 12.38M | 10.48M | -25.97M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7.10M | 5.35M | 5.10M | 693.00K | 623.00K |
| Repurchase of Common Stock | -- | -- | -- | -110.00K | -110.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -646.00K | -153.00K | -153.00K | -17.00K | -153.00K |
| Cash from Financing | 6.45M | 5.19M | 4.94M | 566.00K | 360.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.51M | 828.00K | 304.00K | -11.21M | -49.13M |